Trials / Completed
CompletedNCT01008358
Anti-CTLA-4 Human Monoclonal Antibody CP-675,206 in Patients With Advanced Hepatocellular Carcinoma
Phase II Trial of Anti-CTLA-4 Human Monoclonal Antibody CP-675,206 in Patients With Advanced Hepatocellular Carcinoma
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 20 (actual)
- Sponsor
- Clinica Universidad de Navarra, Universidad de Navarra · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
CP-675,206 (tremelimumab) is a fully humanized monoclonal antibody that binds to activated T lymphocytes and by enhancing their activation may produce a stimulation of the immune response against tumoral or viral antigens. In this clinical trial, the ability of tremelimumab to produce tumor responses among hepatitis C virus-infected patients with hepatocellular carcinoma not amenable to other therapies will be explored. Besides, the effect on the replication of the virus will be analysed.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | CP 675,206 |
Timeline
- Start date
- 2008-12-01
- Primary completion
- 2012-05-01
- Completion
- 2012-05-01
- First posted
- 2009-11-04
- Last updated
- 2012-06-08
Locations
3 sites across 1 country: Spain
Source: ClinicalTrials.gov record NCT01008358. Inclusion in this directory is not an endorsement.